Trademarkia Logo

Canada

C$
Trademark Search in Canada
CONNECTED DOTS IN DIAMOND DESIGN
CONNECTED DOTS IN DIAMOND DESIGN
ADVERTISED

on 8 Nov 2024

Last Applicant/ Owned by

MERCK SHARP & DOHME LLC

126 East Lincoln Ave.P.O. Box 2000Rahway, NJ 07065

US

Serial Number

2061362 filed on 2th Nov 2020

Registration Number

TMA1268189 registered on 8th Nov 2024

Registration expiry Date

8th Nov 2034

Correspondent Address

BORDEN LADNER GERVAIS LLP

Bay Adelaide Centre, East Tower22 Adelaide St. WestTORONTO

ONTARIO

CA

M5H4E3

CONNECTED DOTS IN DIAMOND DESIGN

Trademark usage description

pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for the prevention and treatment of bone, c Read More

Vienna Information


1 . 13 . 1

Armillary spheres, planetaria, astronomic orbits, atomic models, molecular modelsSphères armillaires, planétariums, orbites astronomiques, schémas d'atomes, schémas de molécules

1 . 13 . 15

Atomic models, molecular models, representations of human, animal or vegetal cells, images of bacteria or viruses, DNA helixesSchémas atomiques, schémas de molécules, représentations de cellules humaines, animales ou végétales, images de bactéries ou de virus, hélices d'ADN

26 . 4 . 3

Rhombs or squares standing on one of the corners thereofLosanges ou carrés sur pointe

26 . 4 . 7

Two quadrilaterals, one inside the otherDeux quadrilatères, l'un dans l'autre

26 . 4 . 10

Quadrilaterals containing one or more circles, ellipses or polygonsQuadrilatères contenant un ou plusieurs cercles, ellipses ou polygones

26 . 4 . 11

Quadrilaterals containing one or more triangles or lines forming an angleQuadrilatères contenant un ou plusieurs triangles ou des lignes formant un angle

26 . 1 . 1

CirclesCercles

26 . 1 . 6

Several circles or ellipses, juxtaposed, tangential or intersectingPlusieurs cercles ou ellipses, juxtaposés, tangents ou se coupant

26 . 1 . 24

Circles or ellipses with dark surfaces or parts of surfacesCercles ou ellipses avec surface ou partie de la surface foncée

26 . 3 . 23

Lines or bands forming an angle -- Note: Including chevrons and arrowheads formed by lines or bands.Lignes ou bandes formant un angle -- Note: Y compris les chevrons et les pointes de flèches formées par des lignes ou des bandes.

25 . 7 . 1

Surfaces or backgrounds covered with repeated geometrical figures or designsSurfaces ou fonds couverts de figures ou de motifs géométriques répétés

25 . 7 . 6

Surfaces or backgrounds covered with circles or ellipsesSurfaces ou fonds couverts de cercles ou d'ellipses

26 . 7 . 4

Circles or ellipses with lines (except 26.7.3)Cercles ou ellipses avec lignes (excepté 26.7.3)

Classification Information


Class [005]
Pharmaceutical preparations and substances for use in Oncology; Pharmaceutical preparations and substances for the prevention and treatment of bone, cardiovascular, hematological, hepatological, immunological, gastrointestinal, musculoskeletal, nephrological, oncological, ophthalmic, pulmonary, renal, respiratory, and urological diseases and disorders; Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; Pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, namely bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, psoriasis, eczema, and dermatitis; Pharmaceutical preparations and substances for the prevention and treatment of diseases and disorders of the endocrine system, namely, glucagonoma, growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; Pharmaceutical preparations and substances for the prevention and treatment of genitourinary diseases and disorders, namely, infertility, sexually transmitted diseases, inflammatory pelvic diseases; Pharmaceutical preparations and substances for the prevention and treatment of gynecological diseases and disorders, namely amenorrhoea, dysmenorrheal and diseases and disorders relating to sexual reproduction and fertility; Pharmaceutical preparations and substances for the prevention and treatment of metabolic diseases and disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, arthritis, obesity and hypothyroidism; Pharmaceutical preparations and substances for the prevention and treatment of pain; Pharmaceutical preparations and substances for the prevention and treatment of psychiatric diseases and disorders, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, psychoses and bipolar disorders; Pharmaceutical preparations and substances for the prevention and treatment of Respiratory Syncytial Virus (RSV); Pharmaceutical preparations substances for the prevention and treatment of autoimmune diseases, asthma, cancer and tumors, chronic cough, diabetes, hypertension, insomnia, intestinal infections, skin disorders, namely, dermatitis, skin pigmentation diseases, psoriasis, acne, rosacea, ichthyosis, urticaria and urinary incontinence; Pharmaceutical preparations, namely, antibiotics, anti-fungals, anti-infectives, anti inflammatories, anti-parasitics, and antivirals; Human vaccine preparations; Inhaled pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and disorders


Classification kind code

11

Mark Details


Serial Number

2061362

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 42
on 21st Aug 2024
Advertised
Submitted for opposition 26
on 25th Jul 2024
Approved
Submitted for opposition 27
on 25th Jul 2024
Approval Notice Sent
Submitted for opposition 22
on 17th Jul 2024
Search Recorded
Submitted for opposition 48
on 15th Mar 2024
Agent Changed
Submitted for opposition 135
on 10th Aug 2022
Amendment to Application
Submitted for opposition 287
on 4th Aug 2022
Pre-Assessment Letter Sent
Submitted for opposition 30
on 2th Nov 2020
Filed
Submitted for opposition 1
on 2th Nov 2020
Created
Submitted for opposition 31
on 2th Nov 2020
Formalized